Evaluation of the Effect of Alogliptin on Tissue Characteristics of the Carotid Wall: Subanalysis of the SPEAD-A Trial

[1]  T. Hirano,et al.  Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in experimental animals , 2016, Journal of diabetes investigation.

[2]  A. Shimatsu,et al.  Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects. , 2016, Metabolism: clinical and experimental.

[3]  I. Shimomura,et al.  Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) , 2015, Diabetes Care.

[4]  T. Yanase,et al.  Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury , 2014, Cardiovascular Diabetology.

[5]  G. Paolisso,et al.  Sirtuin 6 Expression and Inflammatory Activity in Diabetic Atherosclerotic Plaques: Effects of Incretin Treatment , 2014, Diabetes.

[6]  S. Weisnagel,et al.  Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. , 2014, Metabolism: clinical and experimental.

[7]  I. Shimomura,et al.  The risk factors associated with ultrasonic tissue characterization of carotid plaque in type 2 diabetic patients. , 2014, Journal of diabetes and its complications.

[8]  M. Nader.  Sitagliptin ameliorates lipid profile changes and endothelium dysfunction induced by atherogenic diet in rabbits , 2014, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  Yasunori Ueda,et al.  The utility of ultrasonic tissue characterization of carotid plaque in the prediction of cardiovascular events in diabetic patients. , 2013, Atherosclerosis.

[10]  T. Hirano,et al.  Preventive Effect of Dipeptidyl Peptidase-4 Inhibitor on Atherosclerosis Is Mainly Attributable to Incretin's Actions in Nondiabetic and Diabetic Apolipoprotein E-Null Mice , 2013, PloS one.

[11]  A. Shimatsu,et al.  A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. , 2013, Metabolism: clinical and experimental.

[12]  N. Marx,et al.  Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe−/− mice , 2012, Diabetologia.

[13]  A. Miyazaki,et al.  Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice , 2011, Diabetologia.

[14]  A. Avogaro,et al.  Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. , 2011, Vascular pharmacology.

[15]  R. Seeley,et al.  GLP-1 and energy balance: an integrated model of short-term and long-term control , 2011, Nature Reviews Endocrinology.

[16]  A. Dear,et al.  A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model , 2011, Diabetes & vascular disease research.

[17]  W. L. Jin,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. , 2011, Biochemical and biophysical research communications.

[18]  A. Nicolaides,et al.  Asymptomatic internal carotid artery stenosis and cerebrovascular risk stratification. , 2010, Journal of vascular surgery.

[19]  A. Nicolaides,et al.  The effect of statins on carotid plaque morphology: a LDL-associated action or one more pleiotropic effect of statins? , 2010, Atherosclerosis.

[20]  H. Satoh,et al.  RETRACTED ARTICLE: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells , 2010, Diabetologia.

[21]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[22]  Nobuyuki Taniguchi,et al.  Standard method for ultrasound evaluation of carotid artery lesions , 2009, Journal of Medical Ultrasonics.

[23]  D. Drucker,et al.  Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.

[24]  A. Dear,et al.  A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. , 2009, The Journal of endocrinology.

[25]  D. Drucker,et al.  Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways , 2008, Circulation.

[26]  Yoshihiro Mukuta,et al.  Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. , 2006, American journal of hypertension.

[27]  H. Kaneto,et al.  Lipid-lowering with atorvastatin improves tissue characteristics of carotid plaque. , 2005, Atherosclerosis.

[28]  J. Beckman,et al.  Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I , 2013, European heart journal.

[29]  P. Libby,et al.  Stabilization of atherosclerotic plaques: New mechanisms and clinical targets , 2002, Nature Medicine.

[30]  Torben V. Schroeder,et al.  Ultrasonic Echolucent Carotid Plaques Predict Future Strokes , 2001, Circulation.

[31]  P. Shah,et al.  Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation, Metalloproteinases, and Cell Death in Human Carotid Plaques: Implications for Plaque Stabilization , 2001, Circulation.

[32]  M. Matsuhisa,et al.  Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease. , 2000, Diabetes care.

[33]  J M Stevens,et al.  Reproducibility of Computer-Quantified Carotid Plaque Echogenicity: Can We Overcome the Subjectivity? , 2000, Stroke.

[34]  M. Kaczmarczyk,et al.  Computer-assisted characterisation of a carotid plaque. , 1999, Medical science monitor : international medical journal of experimental and clinical research.

[35]  T V Schroeder,et al.  Lipid-rich carotid artery plaques appear echolucent on ultrasound B-mode images and may be associated with intraplaque haemorrhage. , 1997, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[36]  M. Davies,et al.  Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. , 1993, British heart journal.

[37]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (2). , 1992, The New England journal of medicine.

[38]  A. Grodzinsky,et al.  Structure‐Dependent Dynamic Mechanical Behavior of Fibrous Caps From Human Atherosclerotic Plaques , 1991, Circulation.

[39]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[40]  V. Fuster,et al.  The pathogenesis of coronary artery disease and the acute coronary syndromes (1). , 1992, The New England journal of medicine.